title: Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report.
authors.forename: M L
authors.initials: ML
authors.lastname: Alcaide
authors.forename: M
authors.initials: M
authors.lastname: Kolber
authors.forename: D
authors.initials: D
authors.lastname: Jayaweera
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000068698:Tenofovir
chemical_list: D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine